Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line

British Journal of Cancer

Volumn 79, Issue 5-6, 1999, Pages 831-837

  Hu, X F ^a   Slater, A ^a   Rischin, D ^a   Kantharidis, P ^a   Parkin, J D ^b   Zalcberg, J ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b AUSTIN HEALTH   (Australia)

Author keywords

Anthracycline analogues; Drug accumulation; Drug resistance; Induction of MDR1 expression; Pgp expression

Indexed keywords

3' DEAMINO 3' MORPHOLINOOXAUNOMYCIN; ANTHRACYCLINE; IDARUBICIN;

ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG RESISTANCE; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; NORTHERN BLOTTING; PRIORITY JOURNAL;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CARUBICIN; CELL SURVIVAL; CLONE CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IDARUBICIN; KINETICS; LEUKEMIA, T-CELL; P-GLYCOPROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0033001765     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690133     Document Type: Article

References (40)

1. Beketic-Oreskovic L, Duran GE, Chen G, Dumontet C and Sikie BI (1995) Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdrl gene activation by the cyclosporin PSC 833. J Natl Cancer Inst 87: 1593-1602
2. Berman E (1993) A review of idarubicin in acute leukemia. Oncology 7: 91-104
3. Berman E and McBride M (1992) Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 79 (1): 3267-3273
4. Bosch I and Croop J (1996) P-glycoprotein multidrug resistance and cancer. Biochim Biophys Acta 1288: F37-F54
5. Carella AM, Carlier P, Pungolino E, Resegotti L, Liso V, Stasi R, Montillo M, Iacopino P, Mirto S, Pagano L, Leoni F, Martelli FM, Raimondo FD, Porcellini A, de Rui L, Nosari AM, Cimino R, Damasio E, Miraglia E, Fioritoni G, Ricciuti F, Carotenuto M, Longinotti M, Defazio D, Fazi P and Mandelli F (1993) Idarubicin in combination with intermediate-dose cytarabine and Vp-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. Leukemia 7: 196-199
6. Chaudhary PM and Roninson IB (1993) Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 85: 632-639
7. Chen G, Jaffrézou JP, Fleming WH, Durán GE and Sikie BI (1994) Prevalence of multidrug resistance related to activation of the MDR1 gene in human sarcoma mutants derived by single-step doxorubicin selection. Cancer Res 54: 4980-4987
8. Chin KV, Chauhan SS, Pastan I and Gottesman MM (1990) Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells. Cell Growth Differ 1: 361-365
9. Chomczynski P and Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159
10. Consoli U, Priebe W, Ling YH, Mahadevia R, Griffin M, Zhao S, Soler RP and Andreeff M (1996) The novel anthracycline annamycin is not affected by P-glycoprotein related multidrug resistance: comparison with idarubicin and doxorubicin in HL60 leukemia cell lines. Blood 88: 633-644
11. de Vries EGE and Zijlstra JG (1990) Morpholinyl anthracyclines: option for reversal of anthracycline resistance. Eur J Cancer 26: 659-660
12. Deuchars KL and Ling V (1989) P-glycoprotein and multidrug resistance in cancer chemotherapy. Semin Oncol 16: 156-165
13. Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic L and Sikie BI (1996) Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res 56: 1091-1097
14. Fardel O, Lecureur V, Daval S, Corlu A and Guillouzo A (1997) Up-regulation of P-glycoprotein expression in rat liver cells by acute doxorubicin treatment. Eur J Biochem 246: 186-192
15. Ferrandis E and Benard J (1993) Activation of the human MDR1 gene promoter in differentiated neuroblasts. Int J Cancer 54: 987-991
16. Gekeler V, Beck J, Noller A, Wilisch A, Frese G, Neumann M, Handgretinger R, Ehninger G, Probst H, Neithammer D (1994) Drug-induced changes in the expression of MDR-associated gene: investigations on cultured cell lines and chemotherapeutically treated leukemias. Ann Hematol 69: S19-S24
17. Grogan TM, Spier CM, Salmon SE, Matzner M, Rybski J, Weinstein RS, Scheper RJ and Dalton WS (1993) P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 81: 490-495
18. Hargave RM, Davey MW, Davey RA, Kidman AD (1995) Development of drug resistance is reduced with idarubicin relative to other anthracyclines. Anti-Cancer Drugs 6: 432-437
19. Horichi N, Tapiero H, Sugimoto Y, Bungo M, Nishiyama M, Fourcade A, Lampidis TJ, Kasahara K, Sasaki Y, Takahashi T and Saijo N (1990). 3′-Deamino-3′-morpholino-13-deoxo-10-hydroxycarminomycin conquers multidrug resistance by rapid influx following higher frequency of formation of DNA single-and double-strand breaks. Cancer Res 50: 4698-4701
20. Hu XF, de Luise M, Martin TJ and Zalcberg JR (1990b) Effect of cyclosporin and verapamil on the cellular kinetics of daunorubicin. Eur J Cancer 26: 814-817
21. Hu XF, Martin TJ, Bell DR, de Luise M and Zalcberg JR (1990a) Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines. Cancer Res 50: 2953-2957
22. Hu XF, Slater S, Wall DM, Kantharidis P, Parkin JD, Cowman A and Zalcberg JR (1995) Rapid upregulation of mdr1 expression by anthracyclines in a classical multidrug-resistant cell line. Br J Cancer 71: 931-936
23. Hu XF, Slater A, Wall DM, Parkin JD, Kanthrarids P and Zalcberg JR (1996) Cyclosporin A and PSC 833 prevent up-regulation of MDR1 expression by anthracyclines in a human multidrug-resistant cell line. Clin Cancer Res 2: 713-720
24. Kohno K, Sato S, Takano H, Matsuo K-I and Kuwano M (1989) The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. Biochem Biophys Res Commun 165: 1415-1421
25. Manzano RG, Wright VK and Twentyman PR (1996) Rapid recovery of a functional MDR phenotype caused by MRP after a transient exposure to MDR drugs in a revertant human lung cancer cell line. Eur J Cancer 32A: 2136-2141
26. Michieli M, Michelutti A, Damiani D, Pipan C, Paspadori D, Lauria F and Baccarani M (1993) A comparative analysis of the sensitivity of multidrug resistant (MDR) and non-MDR cells to different anthracycline derivatives. Leukemia Lymphoma 9: 255-264
27. Mickenna SL and Padua RA (1997) Review: multidrug resistance in leukemia. Br J Haematol 96: 659-674
28. Nielsen C, Maare C and Skovesgaard T (1996) Cellular resistance to anthracyclines. Gen Pharmacol 27: 251-255
29. Nooter K and Sonneveld P (1994) Clinical relevance of P-glycoprotein expression in haematological malignancies. Leukemia Res 18: 233-243
30. 2-terminal protein kinase pathway in cellular response to adriamycin and other chemotherapeutic drugs. J Biol Chem 271: 30950-30955
31. Poeta GD, Stasi R, Aronica G, Venditti A, Cox MC, Bruno A, Buccisano F, Masi M, Tribalto M, Amadori S and Papat G (1996) Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood 87: 1997-2004
32. Rohlff C and Glazer RI (1995) Regulation of multidrug resistance through the c-AMP and EGF signalling pathways. Cell Signalling 7: 431-443
33. Ross DD, Doyle LA, Yang W, Tong Y and Cornblatt B (1995) Susceptibility of idarubicin, daunorubicin and their C-13 alcohol metabolites to transport-mediated multidrug resistance. Biochem Pharmacol 50: 1673-1683
34. Rothenberg M, Mickley LA, Cole DE, Balis FM, Tsuruo T, Poplack D and Fojo AT (1989) Expression of the mdr1/P-170 gene in patients with acute lymphoblastic leukemia. Blood 74: 1388-1395
35. Shustik C, Dalton W and Gros P (1995) P-glycoprotein-mediated multidrug resistance in tumor cells; biochemistry, clinical relevance and modulations. In Molecular Aspects of Medicine, pp. 1-78. Elsvier Science: London
36. Tanimura H, Kohno K, Sato S-i, Uchiumi T, Miyazaki M, Kobayashi M and Kuwano M (1992) The human multidrug resistance 1 promoter has an element that responds to serum starvation. Biochem Biophys Comm 183: 917-924
37. Tsuruo T, Iida H, Tsukagoshi S and Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967-1972
38. Ueda K, Clark DP, Chen C-J, Roninson IB, Gottesman MM and Pastan I (1987) The human multidrug resistance (mdr1) gene: cDNA cloning and transcription initiation. J Biol Chem 262: 505-508
39. Watanabe M, Komeshima N, Naito M, Isoe T, Otake N and Tsuruo T (1991) Cellular pharmacology of MX2, a new morpholino anthracycline, in human pleiotropic drug-resistant cells. Cancer Res 51: 157-161
40. Zalcberg JR, Hu XF, Wall DM, Mirski S, Cole S, Nadalin G, De Luise M, Parkin JD, Vrazas V, Campbell L and Kantharidis P (1994) Cellular and karyotypic characterization of two doxorubicin resistant cell lines isolated from the same parental human leukemia cell line. Int J Cancer 57: 522-528